Volcano to Highlight New Technologies and Clinical Study Results at TCT 2012

The Associated Press

Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced plans to highlight its functional measurement technologies and clinical study results related to Intravascular Ultrasound (IVUS) catheters and Fractional Flow Reserve (FFR) guide wires, at the Transcatheter Cardiovascular Therapeutics (TCT) conference being held in Miami from October 22nd - 26th, 2012.

"In keeping with Volcano's commitment to innovation in providing solutions for complex indications, we will be highlighting our advances in Functional Management and a suite of new products designed to address the most complex clinical indications," commented Scott Huennekens, president and chief executive officer of Volcano. "As key healthcare reforms are now being implemented, it is important, now more than ever, that physicians have the right tools to thoroughly evaluate patients, not only to guide treatment pathways, but to provide evidence supporting their decisions. With the insight our technologies provide, Volcano can help physicians and healthcare institutions answer the growing demand for truly personalized medicine that is appropriate, evidence-based, and accountable. At prior TCT meetings, when, FAME, PROSPECT and FAME 2 were presented, the paradigm of patient care shifted. Results from a number of large, prospective clinical studies that include Volcano IVUS and Functional Management technologies will be presented again this year at late breaking trials and topic-specific clinical sessions that may help physicians guide their future daily decision-making." Volcano highlights the following key events: Key Clinical Presentations -- Monday, October 22, 6:00 p.m. - 8:00 p.m. Featured Clinical Research II RESOLVE: A Multicenter Study Evaluating the Diagnostic Accuracy of iFR Compared to FFR Allen Jeremias, MD, MSc Miami Beach Convention Center, Room C223-224 -- Tuesday, October 23, 11:15 a.m. - 11:30 a.m. Adjunct Imaging and Physiology IVUS Predictors of Stent Thrombosis: Results from the Prospective, Multicenter ADAPT-DES Study Akiko Maehara, MD Miami Beach Convention Center, Room D239 -- Tuesday, October 23, 11:30 a.m. - 11:45 a.m. Adjunct Imaging and Physiology Use of IVUS Reduces Stent Thrombosis: Results from the Prospective, Multicenter ADAPT-DES Study Bernhard Witzenbichler, MD Miami Beach Convention Center, Room D239 -- Wednesday, October 24, 12:45 p.m. - 1:00 p.m. Novel Findings from Randomized and Nonrandomized Studies ADAPT-DES IVUS Substudy: Utility of IVUS in Delineating the Mechanism of and Preventing Stent Thrombosis Akiko Maehara, MD Miami Beach Convention Center, Room D235-236 -- Thursday, October 25, 12:15 p.m. - 12:30 p.m. Plenary Session XVII.

First Report Investigations II ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin

Hyporesponsiveness on Patient Outcomes Gregg W. Stone, MD Miami Beach Convention Center, Main Arena II, Hall D Breakfast Symposia -- Tuesday, October 23, 6:30 am. - 8:00 a.m. Expanding Your Interventional Practice with Peripheral Procedures Julian Javier, MD; Prakash Krishnan, MD; Gregory Mishkel, MD Miami Beach Convention Center, Room D235-236 -- Wednesday, October 24, 6:30 a.m. - 8:00 a.m. The Crucial Role of FFR in the Post-SYNTAX Era Morton Kern, MD; Justin E. Davies, MBBS, PhD; Patrick W. Serruys, MD, PhD Miami Beach Convention Center, Room C227-228 -- Thursday, October 25, 6:30 a.m. - 8:00 a.m. Strategies to Address Guidelines, Necessity and Improve PCI Outcomes David Rizik, MD; Jasvindar Singh, MD; Bernhard Witzenbichler, MD Miami Beach Convention Center, Room D231-232 Image Interpretation with the Experts -- Attendees can learn the art of IVUS image interpretation at sessions conducted each day at the Volcano booth by 'Teach IVUS' creator John McB. Hodgson, MD and noted interventional cardiologist Bruce A. Samuels, MD.

About Volcano Corporation Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Any statements in this release that are not historical facts may be considered "forward-looking statements" including statements regarding the potential benefits of the products and procedures described above, further development and expansion, regulatory approval, commercial release and market adoption of the company's technology, and the impact of clinical and other technical data. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, product introductions, unexpected new data, safety and technical issues, market conditions, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation -0- 10/20/2012 /CONTACT: Media, Edrienne Brandon, +1-858-720-4136, ebrandon@volcanocorp.com, or Investor, +1-650-458-3014 , Neal Rosen, nrosen@volcanocorp.com /Web Site: http://www.volcanocorp.com (NASDAQ-NMS:VOLC) / CO: Volcano Corporation ST: California Florida IN: HEA MTC PHA SU: TDS PDT PRN -- SF96846 -- 0000 10/20/2012 00:47:34 EDT http://www.prnewswire.c

Source URL (retrieved on *03/12/2014 - 9:56am*):
http://www.mdtmag.com/news/2012/10/volcano-highlight-new-technologies-and-clinical-study-results-tct-2012